In this interview Robert Nelson, Associate Director of Science and Innovation at Covance (Geneva, Switzerland) discusses the importance of biomarkers in drug development, describing key aspects in the current guidance and key considerations to make in the development and validation process.
In this interview Ulrich Mayer, Technical Sales Specialist (Bio-Rad laboratories, CA, USA) talks about Bio-Rad’s capabilities with the generation of custom antibodies for assay development.
In this interview, Richard Kay (Wellcome Trust, University of Cambridge, UK) discusses his use of HRMS and QQQ for the analysis of the peptidome.
In this interview Joel Mathews (Ionis Pharmaceuticals Inc., CA, USA) discusses his role in the development of biomarker, PK and immunogenicity assays in the development of protein therapeutics. He explains his interest in the field and explores the use of LBA for biomarker validation
In this interview, Jon Haulenbeek (Bristol-Myers Squibb; NJ, USA) discusses his role as a Group Leader running the Reagent Center of Excellence in the Translational Medicine Division.
In this interview, John Kadavil (US FDA; MA, USA) shares his thoughts on the draft ICH M10 guidance for bioanalytical method validation, indicating how this will change the bioanalytical regulatory landscape.
In this interview, Eric Woolf (Merck; PA, USA) provides an overview of the draft ICH M10 guidance for bioanalytical method validation, indicating why there is a need for new guidance despite many BMV guidance currently being available.
In this interview, Wenying Jian (Janssen Research & Development, Johnson & Johnson; NY, USA) describes the basic principles of hybrid LBA/LC–MS and how this technique can be used to quantify proteins.
Hear more about the recent mass spectrometry product launches from SCIEX announced at ASMS 2019, including the new Acoustic Ejection Mass Spectrometry technology, in this interview with Neil Walsh (SCIEX; MA, USA).